论文部分内容阅读
笔者收集了经内镇证实伴幽门螺杆菌（ＨＰ）感染的消化性溃疡１４０例。随机分为三组，分别使用呋喃唑酮＋得乐冲剂＋雷尼替丁（Ｆ＋ＣＢＳ＋Ｒ组），呋喃唑酮＋得乐冲剂（Ｆ＋ＣＢＳ组），及单用雷尼替丁（Ｒ组）．疗程４周，维持治疗４周。通过近期及一年的随访的治疗效果，其溃疡４周治愈率以Ｆ＋ＣＢＳ＋Ｒ组最高（９７．６％，８２／８４），显著高于Ｆ＋ＣＢＳ组（７５％，２７／３６）和Ｒ组（７０％，１４／２０）（Ｐ＜０．０１）．ＨＰ消失率和胃粘膜炎症病理好转主是Ｆ＋ＣＢＳ＋Ｒ组（８１％，５２．４％）和Ｆ＋ＣＢＳ组（８０．６％，５２．８％）显著高于Ｒ组（５％，１０％）（Ｐ＜０．００１）．停药一年随访结果，溃疡复发率是Ｆ＋ＣＢＳ＋Ｒ组（１３．１％，１１／８４）和Ｆ＋ＣＢＳ组（１５．２％，５／３３）显著低于Ｒ组（１６．７％，１２／１８）（Ｐ＜０．００１）；ＨＰ根除率与溃疡复发率相对应，前两组（８３．８％，８２．８％）明显高于Ｒ组（Ｐ＜０．００１）．作者认为联合使用清除ＨＰ药物（Ｆ，ＣＢＳ）、制酸药物（Ｈ２受体拮抗剂）和胃粘膜保护剂（ＣＢＳ），不仅可有效地提高消化性质疡的近期疗效，而且可以显著降低其复发率。
I collected by the town confirmed with Helicobacter pylori (HP) infection of peptic ulcer 140 cases. The rats were randomly divided into three groups: Furazolidone + Detox + Ranitidine (F + CBS + R), Furazolidone + Detox (F + CBS) and Ranitidine alone (R). Treatment for 4 weeks, maintenance treatment for 4 weeks. The four-week cure rate of ulcer with F + CBS + R group was the highest (97.6%, 82/84), which was significantly higher than that of F + CBS group (75%, 27/36) and R group %, 14/20) (P <0.01). The rate of disappearance and gastric mucosal inflammation were significantly higher in F + CBS + R group (81%, 52.4%) and F + CBS group (80.6%, 52.8%) than in R group (5%, 10% <0.001). The one-year follow-up results showed that the ulcer recurrence rate was significantly lower in the F + CBS + R group (13.1%, 11/84) and F + CBS group (15.2%, 5/33) ) (P <0.001). The eradication rate of HP corresponded with the recurrence rate of ulcer. The former two groups (83.8%, 82.8%) were significantly higher than those in R group (P <0.001). The authors conclude that combined use of Clenbuterol (F, CBS), antacid (H2 receptor antagonist) and gastric mucosal protective agent (CBS) not only improves the short-term curative effect of digestive ulcer effectively but also significantly reduces its recurrence rate.